Treatment of resistance to filgotinib

Filgotinib (Filgotinib) is a drug commonly used to treat rheumatoid arthritis and other autoimmune diseases. Resistance refers to a patient's weakened or ineffective response to treatment with the drug. If drug resistance occurs, the doctor should be informed in time. Since each person's constitution is different and the drug resistance response is different, the doctor may re-evaluate the patient's diagnosis to ensure that the type and severity of the disease are correctly determined and to exclude other possible causes.

Filgotinib is generally well tolerated, with the most commonly reported adverse reactions being nausea, upper respiratory tract infection, urinary tract infection, and dizziness. The frequency of serious infections with filgotinib is low and stable with long-term exposure; the most common serious infection is pneumonia. Your doctor may consider increasing the dose of filgotinib to try to make the treatment more effective. However, this should be done under the guidance of a physician, and the patient needs to be closely monitored for responses and adverse effects. Combining other similar drugs or drugs with different mechanisms with filgotinib may increase the therapeutic effect. Doctors can decide whether to add other drugs based on the patient's specific conditions. If filgotinib is not effective in treating resistant patients, doctors may consider switching to other treatment options, such as other immunosuppressants or biologics.

The original drug filgotinib has not yet been launched in China, and therefore is not included in medical insurance. The Bangladeshi version of the filgotinitine generic drug currently on the market overseas, specifications100mg*30 tablets may cost more than 500 yuan per box (the price may fluctuate due to exchange rates), and its drug ingredients are basically the same as those of the original drug. For more drug information and specific prices, please consult Yaode Medical Consultant.